Using the Non Invasive Technology Magnetic Resonance Elastography for the Diagnosis of Liver Fibrosis Stage

Sponsor
Prof. Ziv Ben-Ari MD (Other)
Overall Status
Unknown status
CT.gov ID
NCT03487159
Collaborator
(none)
140
1
2
13
10.8

Study Details

Study Description

Brief Summary

This study evaluates the ability of Magnetic Resonance Elastography non invasive technology to identify the liver fibrosis stage in patients with chronic liver diseases compared to Shear Wave Elastography and/or Liver Biopsy.

Condition or Disease Intervention/Treatment Phase
  • Device: MRE (Magnetic Resonance Elastography)
N/A

Detailed Description

Recent advances in magnetic resonance imaging (MRI) of the liver have led to improvements in diagnosis of chronic liver diseases. Detection and staging of liver fibrosis has become important; however, until about the last decade, it depended on an invasive liver biopsy. Liver biopsy is limited by high cost, low patient acceptance, interobserver variability during microscopic evaluation, sampling error, poor reproducibility, and, importantly, an invasive nature with a complication rate of 3% and a mortality rate of 0.03%. With the emergence of elastography techniques, the need for liver biopsy has rapidly diminished for diagnosis of clinically significant liver fibrosis. Magnetic Resonance Elastography has gained increasing popularity in recent years, in large part due to its higher technical success and ability to overcome some of the weaknesses of ultrasound-based methods for assessing liver fibrosis.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
140 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
The study model includes 2 study arms: Patients with chronic liver diseases who will undergo a routine liver biopsy, Shear Wave elastography and the MRE in order to evaluate the liver fibrosis stage. Patients with chronic liver diseases who will undergo a routine Shear Wave elastography and the MRE in order to evaluate the liver fibrosis stage. Demographic and clinical information will be collected from the patient's medical files.The study model includes 2 study arms:Patients with chronic liver diseases who will undergo a routine liver biopsy, Shear Wave elastography and the MRE in order to evaluate the liver fibrosis stage. Patients with chronic liver diseases who will undergo a routine Shear Wave elastography and the MRE in order to evaluate the liver fibrosis stage. Demographic and clinical information will be collected from the patient's medical files.
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Using the Non Invasive Technology Magnetic Resonance Elastography for the Diagnosis of Liver Fibrosis Stage
Anticipated Study Start Date :
May 1, 2018
Anticipated Primary Completion Date :
May 1, 2019
Anticipated Study Completion Date :
Jun 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Other: Liver biopsy ,Elastography and MRE

Performance of routine Liver biopsy,Shear Wave Elastography and investigational MRE (Magnetic Resonance Elastography) in order to evaluate liver fibrosis stage.

Device: MRE (Magnetic Resonance Elastography)
The device is using to evaluate liver fibrosis stage

Other: Elastography and MRE

Performance of routine Shear Wave Elastography and investigational MRE (Magnetic Resonance Elastography) in order to evaluate liver fibrosis stage.

Device: MRE (Magnetic Resonance Elastography)
The device is using to evaluate liver fibrosis stage

Outcome Measures

Primary Outcome Measures

  1. Liver Biopsy Result for liver fibrosis grade [Patient will undergo Liver biopsy once during 1 year of the study.]

    Liver Fibrosis score measured by Metavir scale .The Metavir score grades the degree of fibrosis on a 5-point scale from 0 to 4. The activity, which is the amount of inflammation (specifically, the intensity of necro-inflammatory lesions), is graded on a 4-point scale from A0 to A3. Fibrosis score: F0 = no fibrosis F1 = portal fibrosis without septa F2 = portal fibrosis with few septa F3 = numerous septa without cirrhosis F4 = cirrhosis Activity score: A0 = no activity A1 = mild activity A2 = moderate activity A3 = severe activity Liver biopsy will be perfomed only according to physician recommendation.

  2. Magnetic Resonance Elastography (MRE) Result for liver fibrosis grade [Patient will undergo Magnetic Resonance Elastography (MRE) once during 1 year of the study.]

    Liver Fibrosis score determined by liver stiffness in 4 fibrosis grades: >1=any fibrosis, >2=significant fibrosis, >3=advanced fibrosis, 4=cirrhosis

  3. Shear Wave Elastography Result for liver fibrosis grade [Patient will undergo Shear Wave Elastography once during 1 year of the study.]

    Liver Fibrosis score determined by liver stiffness in in 5 fibrosis grades: 0=no fibrosis, >1=any fibrosis, >2=significant fibrosis, >3=advanced fibrosis, 4=cirrhosis

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with chronic liver diseases
Exclusion Criteria:
  • Patients who don't have chronic liver diseases

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sheba Medical Center Ramat Gan Israel 5265601

Sponsors and Collaborators

  • Prof. Ziv Ben-Ari MD

Investigators

  • Principal Investigator: Ziv Ben-Ari, MD, Liver Diseases Center, Sheba M.C

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Prof. Ziv Ben-Ari MD, Head of Liver Diseases Center, Sheba Medical Center
ClinicalTrials.gov Identifier:
NCT03487159
Other Study ID Numbers:
  • SHEBA-17-4749-ZBA-CTIL
First Posted:
Apr 3, 2018
Last Update Posted:
Apr 3, 2018
Last Verified:
Apr 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 3, 2018